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a b s t r a c t
Two classes of Human papillomaviruses (HPV) infect the anogenital track: high risk viruses that are
associated with risk of cervical cancer and low risk types that drive development of benign lesions, such
as condylomas. In the present study, we established quantitative transcriptional maps of the viral
genome in clinical lesions associated with high risk HPV16 or low risk HPV6b. Marked qualitative and
quantitative changes in the HPV16 transcriptome were associated with progression from low to high
grade lesions. Speciﬁc transcripts encoding essential regulatory proteins such as E7, E2, E1\widehatE4
and E5 were identiﬁed. We also identiﬁed intrinsic differences between the HPV6b-associated
condyloma transcript map and that of the HPV16-associated low grade CIN speciﬁcally regarding
promoter usage. Characterization and quantiﬁcation of HPV transcripts in patient samples thus establish
the impact of viral transcriptional regulation on the status of HPV-associated lesions and may therefore
help in deﬁning new biologically-relevant prognosis markers.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Human papillomaviruses (HPV) of high risk type, such as
HPV16, can directly transform mucosal epithelia and are consid-
ered important etiologic agents of cervical, anal and oropharyn-
geal cancers. More than 99% of cervical cancers contain HPV
genomes and express HPV transcripts (Walboomers et al., 1999).
In these lesions, and in cell lines established there from, HPV
transcripts are initiated at the viral regulatory region and contain
the E6 and E7 open reading frames (ORFs) (Schwarz et al., 1986,
1985; Seedorf et al., 1987). Indeed, viral E6 and E7 oncogenic
proteins are predominantly responsible for degradation of the cell
cycle regulatory factors p53, TAp63 and pocket proteins, amongst
other processes contributing to carcinogenic transformation (Ben
Khalifa et al., 2011) (reviewed in (Munger and Howley, 2002;
McLaughlin-Drubin and Munger, 2009; Howie et al., 2009)). In
addition, continuous expression of E6 and E7 is necessary for
maintenance of the transformed phenotype in cell culture. In
patients, the carcinogenic progression induced by HPV is a multi-
step process, starting with infection of the keratinocytes forming
the basal layer of the epithelium, followed by the development of
low and high grade precancerous lesions (Cervical Intraepithelial
Neoplasia or CIN), and eventually fully-ﬂedged carcinoma of either
Squamous Cell Carcinoma (SCC) or adenocarcinoma (ADC) types.
Carcinogenic progression requires persistent HPV infection and is
thought to be associated with major rearrangements in the HPV
transcriptome, leading eventually to sole expression of E6 and E7.
However, little is known about the nature of these rearrange-
ments. To date, viral transcription within the high risk genotypes
HPV16, 18 and 31 has most commonly been studied in vitro in cell
lines or keratinocytes differentiated in 3D raft cultures (Schwarz
et al., 1985; Milligan et al., 2007; Baker et al., 1987; Zheng and
Baker, 2006; Smotkin and Wettstein, 1986; Gray et al., 2010; Wang
et al., 2011; Schmitt et al., 2011). A small number of cell lines have
also been derived from lower grade lesions containing non-
integrated episomal high risk HPV genomes or from benign
condylomas associated with low risk HPV types genomes
(Milligan et al., 2007; Bedell et al., 1991); HPV16 transcripts have
been mapped in one such line (Milligan et al., 2007; Doorbar et al.,
1990) but the extent to which these data reﬂect the in vivo
situation remains unclear. Moreover, these studies cannot address
the important question of how the transcript map might evolve
during carcinogenic progression, and so any association between
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/yviro
Virology
http://dx.doi.org/10.1016/j.virol.2014.05.026
0042-6822/& 2014 Elsevier Inc. All rights reserved.
n Corresponding author.
E-mail address: jean.pierre.abastado@gmail.com (J.-P. Abastado).
Virology 462-463 (2014) 14–24
changes in HPV transcription and in vivo oncogenesis remains
undeﬁned. Recent data from our lab suggest that loss of E2 protein
expression, which is common in cervical cancer (Xue et al., 2010), is
unexpectedly independent of the disruption of the E2 gene that
occurs during integration of the viral genome in 40% of HPV16-
associated cancers (Xue et al., 2012; Das Ghosh et al., 2012). To
understand this, better knowledge of the structure of viral transcripts
is needed, and of their temporal regulation during cancer progression,
in particular regarding expression of E1\widehatE4 and E2 transcripts
relative to that of E6 and E7. The E1\widehatE4 protein is highly
expressed in the upper layers of differentiated cells in CIN but not in
SCC (Doorbar, 2005); the E2 protein is also expressed in CIN in
intermediate and upper epithelial layers, while expression of E7
mainly occurs in lower layers and in the full thickness of the SCC. This
pattern of expression thus links E1\widehatE4 and E2 to cellular
differentiation, while in contrast E7 expression occurs in undiffer-
entiated proliferative epidermal cells. However, how transcripts of
these different viral proteins are expressed and regulated in vivo has
not been resolved. In this study we present a comprehensive descrip-
tion of HPV transcriptomes using RNASeq analyses of HPV16-
associated patient lesions and a HPV6b-associated condyloma.
Results and discussion
Comparison of transcript maps from HPV16-associated cervical
lesions with published in vitro HPV16 transcript maps
RNA was extracted from 20 fresh biopsies obtained from
patients with HPV-associated lesions. Histological grades and HPV
genotypes of all samples were determined with three HPV16-
associated lesions (one CIN2, one CIN3 and one SCC), and one
HPV6b-associated low grade condyloma selected for deep sequen-
cing. Serial sections of the HPV16-associated CIN2 and SCC and
HPV6b-condyloma samples used for the deep RNA sequencing
were subjected to both IHC to detect viral E2 protein and the
p16ink4 cellular marker (a surrogate marker indicating expression
of the viral E7 protein), and in situ hybridization (ISH) for viral
DNA detection, as previously described (Xue et al., 2010, 2012)
(Fig. 1). These results conﬁrmed our previous observations of E2
protein expression in the intermediate and upper layers of CIN2
but not in SCC, while in contrast p16ink4 is detected in the 2/3
lower layers of CIN2 and uniformly in SCC samples. HPV DNA
detected by ISH showed episomal ampliﬁcation in the upper layers
of CIN2 (uniform labeling of the entire nuclei) and an integrated
pattern in the SCC (punctate labeling). These labeling patterns
were also remarkably similar in the HPV6b-associated condyloma
and HPV16-associated CIN2, especially regarding the concomitant
expression of E2 and viral DNA replication, which is shown here
in the HPV6-associated condyloma using an HPV16 E2 antibody
that cross reacts with HPV6 E2 protein as reported previously
(Lai et al., 2013). The CIN3 lesion sample was not of sufﬁcient size
for sectioning.
In the three HPV16-associated lesions, a total of 21 distinct viral
transcripts were identiﬁed (Figs. 2 and 3, Table 1). Thirteen (A–Q,
Fig. 2) exclusively covered the early region of the HPV16 genome
and used the early polyadenylation site nt 4215 of the viral
genome. These “early transcripts” have been reported previously
(Zheng and Baker, 2006). In addition 8 “late transcripts” were
detected, of which 2 were already known (P and Q), and 6 were
newly identiﬁed here (represented with the preﬁx “cuff”). Seven of
these late transcripts used the polyadenylation site at nt 7321,
while the remaining transcript (cuff21) corresponded to an almost
full-length covering of the genome with undeﬁned coding capacity
(Fig. 3). The total absolute abundance of all viral transcripts was
1200 FPKM (Fragments Per Kilobase of transcript per Million
fragments mapped) in CIN2, 120 in CIN3 and 800 in SCC
(Table 1). Remarkably, 16 of the 21 transcripts used the strong E1
splice donor at nt 880 (Figs. 2 and 3).
Comparison of the HPV16 transcriptome in CIN and SCC lesions
Our data conﬁrmed that all HPV16 transcripts are polycistronic, as
reported earlier (Zheng and Baker, 2006). To determine the coding
capacity of the 20 deﬁned transcripts, we searched for translation
initiation sequences (AUG with Kozak's motif) located at least 18 nt
downstream from the 50 end of the transcripts. The latter length is
considered the minimal size of mRNA 50UTR required for efﬁcient
landing of the ribosomal complex, while the average size 50UTR in
eukaryotic transcripts is 200 nt (Chatterjee and Pal, 2009). In
addition, and in accordance with the general scanning model of
RNA translation in eukaryotic cells, we only considered the 50 most
proximal AUG with “Kozak motif”. The coding capacity of the 20
mRNAs is given in Fig. 2 for the “early transcripts” and in Fig. 3 for the
“late transcripts”. The relative abundance of transcripts in the three
analyzed HPV16-associated lesions is given in the right part of
Figs. 2 and 3, with the absolute values presented in Table 1.
Eight of the 20 HPV16 transcripts were putative mRNAs
encoding the E7 protein. The most frequently used transcription
start sites (TSSs) map to around nt 97 and nt 670, which have both
been previously described. P97 is the main promoter for transcrip-
tion of E6 and E7 in HPV16-associated cervical carcinoma cell lines
SiHa and Caski (Smotkin and Wettstein, 1986; Smotkin et al., 1989)
and in transfected cells (Romanczuk et al., 1990). The P670
promoter has also been deﬁned as a differentiation inducible
promoter (Grassmann et al., 1996). The use of upstream start sites
such as 4, 10 or 36 (Fig. 3) has also been proposed but while our
approach did not focus on precise determination of the start site
for every transcript, we did observe that 5–7% of all transcripts
started upstream of P97 in SCC and CIN3 (discussed below).
Interestingly, while transcription starting at P97 is repressed by
E2 (Romanczuk et al., 1990; Thierry, 2009), initiation at the other
promoters, either downstream or upstream, was predicted to be
insensitive to E2 repression, being located away from the E2
binding sites.
Remarkably, none of the “late transcripts”, deﬁned as tran-
scripts terminating at the “late” polyadenylation site, used the P97
TSS. Instead, they made use of putative TSSs at upstream or
downstream positions (Fig. 3). These “late transcripts” represented
a relatively small fraction of the total viral RNAs and are relatively
more represented in the CIN2 lesion (10% of the total transcripts)
than in CIN3 and SCC (3–4%) (Table 1).
Description of HPV16 transcripts encoding early proteins
E6: None of the late transcripts and only three early transcripts
(A, F and K) contained a full length E6 ORF, as all other transcripts
were interrupted within E6 at the splice donor located at nt 226
(Fig. 4A). These transcripts started at TSS 97, which is only 7 nt
upstream of the E6 AUG initiation codon and thus is unlikely to be
an efﬁcient translation initiation site for E6 protein. Moreover
these transcripts were only evident in the SCC and CIN3 samples
where they represent only 4% of the total transcripts, with
transcript A being the most abundant (Fig. 2). As approximately
7–8% of total viral transcripts began upstream of P97, especially
visible in the SCC sample (Fig. 4B), it is therefore possible that the
E6 transcripts may also have been initiated upstream of P97. In fact
there are two major putative upstream putative TSSs, at nt 36 or
nt 46, that could give rise to transcripts containing leader sequences
of 70 nt that would allow efﬁcient translation of E6. The relative
scarcity of full length E6 transcripts in HPV-associated genital
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lesions has been reported before (Bohm et al., 1993; Nilsson et al.,
1996).
E7: In sharp contrast to E6, E7 transcripts are highly represented
both in terms of absolute number (8) and relative abundance in the
three clinical samples (Table 1). As expected for the major onco-
genic protein, the highest expression of E7 transcripts was observed
in CIN3 and SCC, where they accounted for 45% and 56% of all
viral transcripts respectively (Fig. 2 and Table 1). Five E7 transcripts
started at P97 and terminated at the “early” polyA site, with
transcript B being the most prominent (44% in SCC) (Fig. 2). These
transcripts are predicted to be sensitive to E2 repression, and they
appeared to be ampliﬁed in CIN3 and SCC where E2 is either not
expressed or is expressed but at low levels compared to in CIN2.
However, in CIN1 and CIN2, expression of E2 and E7 proteins is
normally spatially separated within the epithelium thus making E7
transcription via the use of the P97 promoter possible (Xue et al.,
2010). Interestingly, three putative E7 transcripts were also found
among the late transcripts described in Fig. 3, although they were
less abundant and all contained the downstream ORFs encoding
capsid proteins (Fig. 3 and Table 1). When the levels of E6 and E7
transcripts were compared, it was apparent that E7 transcripts are
well expressed in all lesions where they are over 10-fold more
abundant than E6 transcripts in high grade lesions while E6
transcripts are undetectable (under the threshold) in CIN2
(Table 1) in accordance with the semi-quantitative data obtained
by in situ hybridization reported earlier (Nilsson et al., 1996).
E2: We recently described detection of the E2 protein in HPV16-
associated clinical samples and found high levels of expression in
CIN1 and CIN2 but very low or complete absence of protein
expression in CIN3 and SCC despite presence of abundant tran-
scripts containing E2 sequences (analyzed by the nanostring tech-
nology) (Xue et al., 2012). As shown in Figs. 2 and 3, all viral
transcripts contained sequences covering the overlapping E2 and E4
ORFs between 3400 and 3632, though only eight of these
transcripts (F–P) contained a complete E2 ORF. Furthermore, only
transcripts J and P possessed the E2 translational initiation codon at
the optimal position within the transcripts for efﬁcient translation.
While E2 transcripts represented 2% of the total viral transcripts
in CIN2, they were undetectable in SCC (Table 1 and Fig. 2).
Interestingly, transcript P, which is initiated at nt 670 and should
therefore be insensitive to E2 repression, was the best expressed
putative E2 transcript in CIN2 and CIN3, while it was not expressed
in SCC. These data reﬂect the fact that bona ﬁde E2 transcripts are
relatively less abundant than the total number of transcripts
containing the complete E2 ORF (F-P Fig. 2), which themselves
are globally more abundant in SCC (8%) than in CIN2 (5%). This
reinforces the point that HPV E2 transcription is a poor marker for
gene expression and presence of the protein (Xue et al., 2012).
E1\widehatE4: A total of 6 transcripts (A, B, C and Q, R, S) were
spliced between nt 880 in E1 and nt 3358 in front of E4, thus
possessing coding capacity for the E1\widehatE4 protein, which is
comprised of the ﬁrst 5 amino-acids of E1 fused to E4 (Zheng and
Baker, 2006; Doorbar et al., 1986; Doorbar et al., 2000). However,
in only 3 of these transcripts (Q, R and S), was the E1\widehatE4
AUG in a favorable position to be translated (Figs. 2 and 3). The E1
\widehatE4 protein is highly expressed speciﬁcally in the most
differentiated layers of low grade lesions and is used as a marker of
productive viral infection (Doorbar, 2005). Therefore, and as for
the E2 mRNAs, the quantitative data showing higher expression of
the E1\widehatE4 transcripts in CIN2 compared to CIN3 and SCC is
in agreement with the known protein expression pattern (Fig. 2
and Table 1). In the “early” transcripts map, the E1\widehatE4
messenger Q was the most highly expressed transcript in CIN2,
representing 80% of all transcripts, while its expression was
Fig. 1. Expression of HPV E2 proteins, cellular p16INK4 and viral DNA in the human cervical samples used for RNA deep sequencing analyses. Labeled serial sections of the
HPV16-associated CIN2 and SCC lesions alongside the condyloma associated with HPV6b. IHC with the E2 and p16 antibodies (brown color) together with ISH for viral DNA
was carried out as previously described (dark blue for HPV DNA replication, brown for integrated viral DNA) (Xue et al., 2010). No negative control was used for deep seq
analyses and staining of negative samples with the E2 antibody, for both HPV16-associated CIN and HPV6-associated condyloma, were reported previously (Xue et al., 2010;
Lai et al., 2013).
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40% less in CIN3, and lower still in SCC (Fig. 2). Transcript Q was
initiated at TSS 670, and so probably not repressed by E2 even
though co-expression of E2 and E4 proteins does occur in the same
layers of CIN1 and CIN2 lesions.
E5: E5 is a transforming protein whose expression is disrupted
during integration of the viral genome, and is therefore thought to
be mainly expressed in low grade lesions (Venuti et al., 2011). The
location of the E5 ORF, just before the “early” PolyA signal, with no
splicing signal downstream of E4, made its presence obligatory in
all transcripts ending up at the “early” PolyA site (Fig. 2). However,
the only messenger in which E5 AUG is the most 50 is transcript E,
which is spliced between nt 226 in E6 and nt 3356 in front of E4
(Fig. 1). Interestingly the E5 transcript was expressed at compar-
able levels in the 3 samples, showing a gradual increase in CIN3
and SCC (Fig. 2 and Table 1). Detection of the E5 protein has long
been elusive, but a recent report describes its expression in various
in vitro cell models of high and low grade lesions (Sahab et al.,
2012). According to these studies, the level of expression of E5
protein does not drop dramatically with progression from LSIL to
HSIL (Low to High grade Squamous Intraepithelial Lesion) and can
even be found in Caski cells, where HPV16 DNA is integrated
downstream of the E5 ORF, in agreement with the transcript
quantiﬁcation reported here.
Transcription of the capsid proteins
Transcripts able to drive expression of the L1 and L2 capsid
proteins were terminated at the “late” Poly A site nt 7321, which
is located 200 nt downstream of the termination codon of the L1
ORF (Fig. 3). Six out of the 8 late transcripts described in Fig. 3
possessed a complete L1 ORF, using a splice donor at nt 3632 after
the E4 and the splice acceptor at nt 5638, corresponding exactly to
the L1 AUG (Fig. 3). L1 is expected to be expressed only in low
grade CIN, where productive infection occurs and new viral
particles are formed. In only two transcripts (cuff16 and cuff127)
was the L1 AUG the most 50 AUG for translation initiation, and
both were expressed at very low levels in CIN2 and CIN3, but not
in SCC. The most highly expressed putative L1 transcript (S) was
initiated at TSS 670, and could encode both E1\widehatE4 and L1
but with a much more favorable translational efﬁciency for E1
\widehatE4 than L1 due to better availability of its AUG initiation
codon (Fig. 3). A similar transcript, not using the splice donor after
E4, could also code for L2 but was expressed at very low levels and
only in CIN2, where again the E1\widehatE4 translation would be
more favorable.
A major transcriptional rearrangement occurs before CIN3
The relative distribution of the HPV16 transcripts was quite
similar in the CIN3 and SCC lesions: L1-encoding transcripts were
barely detectable in these 2 lesions (Fig. 3), while E7-encoding
transcripts constituted around half of all viral transcripts, followed
by E1\widehatE4- and E5-encoding transcripts (Fig. 2). Transcripts
were differently represented in the CIN2 lesion where E7-
encoding transcripts comprised only 5.3% of the total, while in
contrast E1\widehatE4 transcripts were preponderantly expressed
Fig. 2. Schematic representation of the HPV16 early transcripts according to a previously published map (Zheng and Baker, 2006). Early PolyA (pAE) signal is indicated by a
black dot and the letters correspond to the original nomenclature of the various transcripts as deﬁned in Zheng and Baker (2006). The proposed coding capacity of the
transcripts is indicated as well as the % of total viral RNA that they represent in each clinical sample (CIN2, CIN3 and SCC).
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at 80% (Fig. 2). This indicated that progression from CIN2 to CIN3 is
associated with major qualitative and quantitative rearrangements
of HPV16 transcription as illustrated by the comparison of depth
read proﬁles encompassing only the proximal 1000 nt region of
HPV16 in the three types of lesions (Fig. 4A). These comparable
quantiﬁcations clearly highlight the much lower transcription
covering of the E7 area (between nt 500 and 800) as well as
the almost undetectable transcription over the speciﬁc E6 area
(between nt 226 and 409) in CIN2 when compared to CIN3 and
SCC. In addition, it illustrates the conserved use of previously
published splice donors and acceptors and TSS in all lesions, as
indicated at the top of the read depth proﬁles (Fig. 4A). Quanti-
tative distribution of transcripts given by read depth proﬁles over
the full HPV16 sequence obtained in CIN2 and SCC conﬁrmed
very different patterns (Fig. 4B): the E6 and E7 ORFs were more
transcribed in SCC, while the strong splicing for E1\widehatE4 was
used in both samples. Transcripts in the late region, between nt
4000 and late polyA at 7158 were only detected in the CIN2
sample (Fig. 4B).
Further analyses of the transcripts in HPV16 samples conﬁrmed
that integration of the HPV16 viral genome had occurred only in
the SCC sample, in agreement with the ISH shown in Fig. 1.
However the SCC sample was heterogeneous and only 20% of
the cells exhibited overt viral genomic integration signal. Never-
theless, sequences of the transcripts in the SCC sample allowed us
to determine the integration sites in both the viral and cellular
genomes. Two integration sites were found in the viral genome:
one at nt 3505 in E2 and a second at nt 3913 in E5. These
integration events gave rise to fusion transcripts between the
early HPV16 region and cellular genome, as depicted in Fig. 3B,
Fig. 3. (A) Schematic representation of the HPV16 “late transcripts” ending at the late PolyA signal, indicated as a black dot (pAL). All transcripts are newly described and use
the previously unidentiﬁed putative TSSs indicated by red arrows on the sequence. Distinct splice donor at nt 3632 and acceptor at nt 5538 are used for these transcripts. An
almost full length transcript of undeﬁned structure is also shown. The proposed coding capacities of the transcripts are indicated alongside the % of total viral transcripts that
each represents in the three HPV16-associated clinical samples (CIN2, CIN3 and SCC). (B) Sequences of the viral–cellular junctions of the transcripts found at the sites of viral
sequences integrated in the cellular genome in the SCC sample.
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which were present in amounts below the threshold used for
quantiﬁcation of the viral transcripts as reported in Table 1 and
Figs. 2 and 3.
Minor transcripts
No transcripts coding for E1 were detected in our data set. An
E1-encoding transcript has yet to be described for HPV16 and the
corresponding transcript in HPV18, grown in vitro in raft cultures,
has only recently been identiﬁed (Wang et al., 2011). This HPV18
transcript is spliced in E6 and is among the rare transcripts ending
at the early Poly A that are not spliced out at nt 880 in the E1 ORF
(Wang et al., 2011). The absence of E1 transcript is particularly
puzzling in the case of the CIN2 lesion where viral DNA replication
commonly occurs (Fig. 1). Since E1 is a helicase required, together
with E2, for viral genome ampliﬁcation we would also expect the
E1 protein to be present in comparable amounts to the E2 protein
and its transcripts. Global depth read coverage of the transcripts
indicated that there is indeed detectable transcription over the E1
region (between nt 880 and 2614) above background (Fig. 4B).
Moreover, and as expected for an ORF required for viral replication,
E1 transcription was higher in the CIN2 biopsy than in the SCC
(Fig. 4B). In addition this level of transcripts was comparable to
that seen over the 50 part of the E2 ORF (before the highly
transcribed E4, between nt 2756 and 3356) (Fig. 4B). We therefore
favor the interpretation that E1 is signiﬁcantly expressed in CIN2,
but that the informatics tools used in this study to identify
individual transcripts, did not permit precise mapping of the
HPV16 E1-encoding transcripts. One transcript that was found in
the three HPV16 samples (cuff21) at 3–4% expression levels
could contain different species, including the E1 transcript, but its
structure was not well deﬁned. No E1 and E2 transcripts have been
previously detected in HPV16-associated lesions of low or high
grades (Bohm et al., 1993; Nilsson et al., 1996).
Mapping of viral transcripts of a HPV6b-associated condyloma and
comparison with HPV16-associated CIN2
We used the same deep sequencing method to map the viral
transcripts in a HPV6b-associated benign condyloma that
expressed the E2 protein and exhibited viral DNA ampliﬁcation
(Fig. 1). The HPV6b transcripts map was constructed using pre-
viously published data including data on the closely-related HPV11
(Baker and Calef, 1996; Chow et al., 1987; Renaud and Cowsert,
1996; Sherman et al., 1992). As noted in these previous reports, the
most abundant transcript was transcript A, encoding the E1\wide-
hatE4 protein, followed by transcript M, which we allocated to E5.
The E1\widehatE4 protein and transcripts have been detected
in abundance in all kinds of low grade HPV-associated lesions
(Doorbar, 2005; Bohm et al., 1993; Nilsson et al., 1996; Stoler et al.,
1992; Stoler et al., 1989).
Surprisingly, the total amount of viral RNA extracted from this
lesion was 14-fold greater than from the HPV16-associated CIN2
lesion, which exhibited the highest transcript levels among the
HPV16-associated lesions (1200 total transcripts in CIN2 vs 17000
in condyloma) (Table 1 and Fig. 5). The second unexpected result was
that the main early promoter, around nt 90 in front of E6, did not
seem to be highly used as mapping of the 50 ends of the transcripts
gave rise to continuous ﬂat readings from an upstream start site at
nt 16 (Fig. 5B). Transcription initiated at the P90 promoter has been
shown to be repressed by E2 similarly to transcription from the
equivalent P97 in HPV16 in transfected cells (Dong et al., 1994). In
contrast, the P715 promoter, within E7, is used for transcription of over
90% of the transcripts and is probably not susceptible to repression by
Table 1
Total amounts (FPKM) of transcripts within the three HPV16-associated lesions and the relative expression of each transcript in the 3 different lesions.
Transcript TSS Proposed coding
capacity
FPKM % of transcripts
CIN2 CIN3 SCC CIN2 CIN3 SCC
A 97 E6 0.00 4.54 30.67 0.0 3.8 3.9
B 97 E7 29.37 39.70 345.95 2.4 33.3 44.4
C 97 E7 0.00 2.83 21.49 0.0 2.4 2.8
E 97 E5 24.34 4.72 49.16 2.0 4.0 6.3
F 97 E6 0.00 0.35 3.13 0.0 0.3 0.4
G 97 E7 1.76 5.16 31.47 0.1 4.3 4.0
H 97 E7 0.00 0.68 8.45 0.0 0.6 1.1
J 97 E2 0.00 0.21 0.00 0.0 0.2 0.0
K 97 E6 0.00 0.20 1.57 0.0 0.2 0.2
L 97 E7 34.11 3.55 15.95 2.8 3.0 2.0
M 97 E7 0.00 0.62 5.41 0.0 0.5 0.7
P 670 E2 27.39 1.28 0.00 2.2 1.1 0.0
Q 670 E1\widehatE4 974.49 49.37 238.92 79.8 41.4 30.7
R 670 E1\widehatE4, L2 3.78 0.00 0.00 0.3 0.0 0.0
S 670 E1\widehatE4, L1 63.93 0.00 0.00 5.2 0.0 0.0
CUFF11 4 E7, L1 9.28 0.00 4.16 0.8 0.0 0.5
CUFF12 4 E7, L1 7.87 0.36 1.42 0.6 0.3 0.2
CUFF127 1127 L1 1.83 0.07 0.00 0.1 0.1 0.0
CUFF13 10 E7, L1 0.00 0.83 0.00 0.0 0.7 0.0
CUFF16 36 L1 0.00 0.12 0.00 0.0 0.1 0.0
CUFF21 4 ND 43.58 4.51 21.35 3.6 3.8 2.7
Total transcripts (21 transcripts) 1221.72 119.12 779.09 100.0 100.0 100.0
Total E2 (2 transcripts) 27.39 1.49 0.00 2.2 1.3 0.0
Total E1\widehatE4 (3 transcripts) 1042.20 49.37 238.92 85.3 41.4 30.7
Total E5 24.34 4.72 49.16 2.0 4.0 6.3
Total L1 (6 transcripts) 82.91 1.38 5.58 6.8 1.2 0.7
Total L2 3.78 0.00 0.00 0.3 0.0 0.0
Total E6 (3 transcripts) 0.00 5.09 35.37 0.0 4.3 4.5
Total E7 (9 transcripts) 82.38 53.73 434.30 6.7 45.1 55.7
Ratio E6/E7 0.00 0.09 0.08
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steric hindrance via binding of E2, as was demonstrated for HPV16
and HPV18 early promoters (Thierry, 2009) (Fig. 5).
Using the same translation rules as described above for the
HPV16 samples, we found that the prominent transcript (A) codes
for E1\widehatE4 and represents 75% of the total viral tran-
scripts, and that the second most abundant transcripts (M), coding
for E5 represents 10% of all transcripts. Interestingly, the two E1
and E2 transcripts were expressed at similarly low abundance of
2% of total and were initiated at a putative TSS that is not
sensitive to E2 repression, which allowed co-expression of the two
proteins in the same cells that is consistent with their concerted
roles in viral DNA replication. The HPV16-associated CIN2 and
HPV6-associated condyloma samples used for deep sequencing
show quite comparable levels of expression of both p16 and E2 as
well as similar HPV DNA replication in the upper most differen-
tiated layers (Fig. 1). When depth read maps of these samples were
compared, transcripts distribution were similar with E1\wide-
hatE4 transcripts being the most abundant (80%) while E7 is
expressed at 10-fold lower levels (Fig. 5B). However, in contrast
with the HPV16-CIN2 the full-length E1 transcript was found in
HPV6b-condyloma, while the level of expression of E2 (2%) was
comparable in both types of lesions (Fig. 5A).
Fig. 4. Quantitative data from the comparative deep sequencing of the HPV16 samples. (A) Coverage of the ﬁrst 1000 bp of the HPV16 genomic sequence by transcripts is
shown for the three HPV16-associated samples (the total RNA contents were equalized for better comparison). Previously published transcription start sites (TSS) and splice
donors (SD) or acceptors (SA) are shown at the top of the panel together with their position in the HPV sequence. (B) Comparison of the read depth maps of the transcripts in
the HPV16-associated CIN2 and SCC aligned with the HPV16 genomic sequence at their original quantitative transcript levels of a total of 600 for the CIN2 and 1000 for
the SCC samples (see Table 1 for exact values).
J. Chen et al. / Virology 462-463 (2014) 14–2420
Fig. 5. Map of the HPV6b transcripts in the condyloma sample. (A) Analysis of the transcripts was carried out as for Figs. 2 and 3 with additional instruction from published
data for the closely-related HPV11 (transcripts A–S) (Baker and Calef, 1996) and description of new transcripts (cuff). (B) Comparison of the HPV6b transcripts quantitative
proﬁle with that of HPV16-associated CIN2 where total transcript quantities were equalized for better comparison. The HPV6b-associated condyloma gave rise to a total of
17,000 transcripts compared to 600 from HPV16-associated CIN2.
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Comparing read depth transcripts in HPV6b-condyloma and
HPV16-CIN2 clearly showed that in both cases there are transcripts
covering the L2–L1 region, although they were surprisingly rela-
tively less expressed in condyloma than in CIN2 (Fig. 5B). The
relative amounts of E6–E7 transcripts were also comparably low,
with a slightly different pattern due to alternative splicing in
HPV16 E6 but not in HPV6b. A speciﬁc E7 transcript initiated at the
E6 putative internal TSSnt 280, as previously described in an
HPV11-associated cell line (Smotkin et al., 1989), was relatively
abundant (6%) compared to the putative E6 transcripts which
altogether represented only 1% of the transcripts (Fig. 5A). In
conclusion, all viral genes are transcribed in this HPV6b-associated
condyloma, leading to the hypothesis that all viral proteins could
be expressed in low risk HPV-associated lesions (Fig. 5). It will be
interesting to compare viral expression in various layers of the
lesions in both CIN and condyloma as well as methylation status of
the viral genome which is thought to play a crucial role in
transcriptional regulation (Vinokurova and von Knebel Doeberitz,
2011; Kalantari et al., 2014) to better understand differential
expression of the viral genes and its relationship with epidermal
proliferation and differentiation.
Comparison of HPV and cellular transcript abundance
Both HPV and cellular transcripts were detected by sequencing.
The abundance of total transcripts followed a similar distribution
pattern in CIN2, CIN3, SCC and HPV6b-associated condyloma
(Supplementary Fig. S1). In particular, HPV transcript abundance
was much higher than the 95% quantile of the entire transcrip-
tome in all four samples (Supplementary Fig. S1). This observation
suggested that HPV transcript expression was not minor compared
to cellular transcripts, especially in low grade lesion CIN2 and
benign condyloma.
Conclusion
We used deep sequencing to construct a quantitative map of
HPV transcripts in three HPV16-associated lesions with increasing
histological grades: CIN2, CIN3 and SCC, and one benign lesion
associated with low risk HPV6b. Our results show that the HPV16
transcriptome in cervical lesions signiﬁcantly differs from that
proposed by studies in cell lines. Moreover, we uncovered impor-
tant differences in the transcriptome between the lower grade
CIN2, and the higher grade CIN3 and SCC. We identiﬁed speciﬁc
transcripts for the HPV16 early ORFs including E1\widehatE4 and
E2 transcripts that were more highly expressed in the CIN2 than in
the SCC sample. As expected, transcription of E2 found in CIN2
correlated with relatively lower transcription of E7, while this
situation was reversed in CIN3 and SCC where E7 transcripts were
ampliﬁed by 8–10-times compared to CIN2, and the speciﬁc E2
transcript was absent in SCC. We further compared the HPV16
transcriptome in the CIN2 lesion with the transcriptome of low
risk HPV in an HPV6b-associated condyloma. Comparable pre-
ponderant (80%) expression of E1\widehatE4 transcripts
initiated at the downstream TSS in E7 (nt 670 in HPV16 and nt
715 in HPV6) was evident, thus representing a hallmark of low
grade lesions in both high risk and low risk viruses. Interestingly
the main E2 transcript was also initiated at the same downstream
putative TSS, although less abundantly than E1\widehatE4. There
have been 3 previous reports on RNAseq of HPV lesions. However
the ﬁrst one looked at a single sample containing HPV58, and did
not use splice read mapping nor transcript assembly/abundance
software (Li et al., 2013); the second looked for HPV reads without
consideration of speciﬁc transcripts (Arron et al., 2011); and the
third was concerned with viral DNA integration sites in the cellular
genome and again not with speciﬁc viral transcripts (Khoury et al.,
2013). Thus, this report is the ﬁrst analysis of the structures and
relative quantiﬁcations of the viral transcripts in patients' lesions
aiming to facilitate interpretation of the regulatory pathways
leading to oncogenic progression.
Materials and methods
Ethics statement
The study was approved by institutional review boards of KK
Hospital SingHealth (CIRB 2010/517/B). The present study only
included adult subjects who provided written informed consent.
Tissue specimens
Patient specimens were obtained from the KK Women's and
Children's Hospital (Singapore) and fresh biopsies were immediately
treated for RNA extraction or ﬁxed in neutral buffered formalin before
embedding in parafﬁn for histology. Diagnosis of specimens was
validated by 2 pathologists according to the classiﬁcation criteria of
World Health Organization.
Immunohistochemistry
Consecutive sections of parafﬁn-embedded tissue samples were
labeled with puriﬁed anti-HPV16E2C (1/50) and anti-p16INK4 (clone
JC8, Santa Cruz) (1/100) antibodies as previously described (Xue
et al., 2010, 2012). in situ hybridizations (ISH) were performed with
broad spectrum HPV biotinylated DNA probe sets able to detect
11 types of anogenital HPV (ref: Y1401, Dako), according to the
manufacturer's guidelines. Two different ISH detection kits were
used: one for detection of episomal HPV DNA (ref: K0601, Dako)
and the other for detection of integrated copies, Genpoint Tyramide
Signal Ampliﬁcation System (ref: K0620, Dako).
DNA extraction and HPV genotyping
DNA extraction was carried out using a column-based protocol
with QIAamp DNA FFPE Tissue Kit (QIAGEN, Germany), according
to the manufacturer's instructions. Genotyping was performed
using the commercial HPV GenoArray test kit (Hybribio Limited,
Hong Kong).
Preparation of RNA samples for sequencing
Total RNA was extracted using the Ambion mirVana miRNA
Isolation Kit. The integrity of total RNA was assessed by Agilent
Bioanalyzer; only samples with RINZ7.6 were selected for the
analysis. cDNA libraries were generated with 300 ng of total
RNA and 2 ml of a 3:1000 dilution of ERCC RNA Spike in Controls
(Ambion). The Illumina TruSeq™ RNA sample preparation kit
version 2 was used according to the manufacturer's protocol, with
the following modiﬁcations: 12 PCR cycles of ampliﬁcation and the
addition of 2 rounds of Agencourt Ampure XP SPRI bead puriﬁca-
tion (Beckman Courter). The Agilent Bioanalyzer DNA 1000 kit was
used to verify the length of the cDNA libraries. The four libraries
were sequenced as multiplexes (3 samples/lane) on an Illumina
HiSeq2000 using a paired-end run (251) and the SBS kit v3.
Data analysis
Curation of known transcript annotations
The annotations of known HPV16 and HPV6b transcripts were
obtained from in vitro studies (Zheng and Baker, 2006; Baker and
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Calef, 1996). However, initial analysis suggested these datasets may be
incomplete, so we carried out manual curation of the annotations by
searching for reads spanning the splice junctions and examining the
donor–acceptor site sequences. We curated the known transcription
map of HPV11. We inspected all the known splice sites of HPV11 and
discovered that our HPV6b sequencing data did not have read support
for any of these splice sites: 1272–3325 (transcript F), 1272–3377
(transcript H), and 3593–5771 (transcript J). In addition, these loci of
HPV6b did not have the donor (GU) and accepter (AG) sequences
expected of a splice site. In contrast, our HPV6b data had reads
spanning 1278–3325, 1278–3377 and 3596–5789 splice junctions,
which do contain the canonical GU donor site and AG acceptor site.
Therefore, we changed the 1272–3325 junction to 1278–3325 for
transcript F; the 1272–3377 junction to 1278–3377 for transcript H;
and the 3593–5771 junction to 3596–5789 for transcript J. The
curated annotations of known HPV16 and HPV6b transcripts are
given in Supplementary Tables S1 and S2.
Mapping and transcript assembly
Quality check (QC) of raw reads was performed using FASTQC
and all libraries passed. A hybrid reference genome, named
hg19HPV, was built by combining hg19 and genome sequences
of 28 HPV subtypes (Supplementary Table S3) downloaded from
NCBI. Similarly, a hybrid gtf ﬁle containing annotations of known
gene models and transcripts was generated by combining UCSC
known human genes and the above curated HPV transcripts. Raw
reads were mapped to hg19 HPV using Tophat (Trapnell et al.,
2009). Tophat alignment was run allowing novel junction discovery
and guided by the annotations of known gene models and tran-
scripts. With the aligned reads, we estimated the relative abun-
dance of transcripts using Cufﬂinks (Trapnell et al., 2010) guided by
annotation of known transcripts and allowing for novel transcript
assembly. The FPKM (Fragments Per Kilobase of transcript per
Million fragments mapped¼[# of fragments]/[length of transcript
in kilo base]/[million mapped fragments]) values calculated by
Cufﬂinks were used as measures of transcript expression abun-
dance. In RNA-Seq, the relative expression of a transcript is propor-
tional to the count of cDNA fragments that originate from it. These
counts must be normalized to the length of the transcripts and the
sequencing depth of a sample. FPKM provides such normalized
count of fragments. Coding potential of the transcripts was pre-
dicted by six-frame translation. Read depth graphs were generated
with Integrated Genome Browser (Nicol et al., 2009) to visualize the
number of reads covering each nucleotide position.
HPV16
Transcripts of HPV16 were ﬁrst assembled using Cufﬂinks guided
by the curated transcription map (Zheng and Baker, 2006) for CIN2,
CIN3 and SCC independently. Novel transcripts assembled from CIN2,
CIN3 and SCC were then merged using Cuffmerge guided by known
transcripts. The merged transcripts comprised of both known and
novel transcripts were used as guide to re-run Cufﬂinks with novel
transcript discovery disabled. The results from the re-assembling
comprise our ﬁnal transcript map of HPV16.
HPV6b
The transcription map of HPV6b is currently unknown. How-
ever, both HPV6b and HPV11 are low-risk viruses and nearest-
neighbours on the HPV phylogenetic tree (Bernard et al., 2010).
We thus assumed that the transcript map of HPV6b was similar to
the known transcript map of HPV11 and used the transcription
map of HPV11 to guide the analysis of HPV6b. Novel junctions and
isoforms were allowed when running Tophat and cufﬂinks.
Detection of viral–cellular fusion transcripts
Given that we had paired-end data, we analyzed the reads for
the presence of read-pairs where one read aligns to human genome
and another to a viral sequence, as this would be an indication of
viral–cellular fusion transcripts. We detected 152 such read-pairs in
the SCC sample by mapping against the hg19HPV hybrid reference
genome using Bowtie2 (Langmead and Salzberg, 2012). To further
deﬁne the viral–cellular fusion point to base-pair resolution, we
used FusionMap (Ge et al., 2011) to align reads spanning the fusion
junctions.
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